LncRNA SSTR5-AS1 as a Prognostic Marker Promotes Cell Proliferation and Epithelial-to-Mesenchymal Transition in Prostate Cancer

Yuan, Shuai; Bi, J. L.; Zhang, Yangang

doi:10.1615/critreveukaryotgeneexpr.2022042183

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2023

2024

Publication Types

Select...

Article3

Preprint1

Relationship

Self Cite0

Independent4

Authors

Journals

Cited by 4 publications

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

A serum LncRNA signature for predicting prognosis of triple-negative breast cancer

Zhu,

Wang,

et al. 2023

Clinica Chimica Acta

View full text Add to dashboard Cite

A serum LncRNA signature for predicting prognosis of triple-negative breast cancer

Zhu,

Wang,

et al. 2023

Clinica Chimica Acta

View full text Add to dashboard Cite

A thorough understanding of the role of lncRNA in prostate cancer pathogenesis; Current knowledge and future research directions

Haghighi,

Castillo-Acobo,

H Amin

et al. 2023

Pathology - Research and Practice

View full text Add to dashboard Cite

Silent players, loud impact: unveiling the therapeutic potentials of LncRNAs

Kamal,

Swellam,

Shalaby

et al. 2024

J Transl Genet Genom

View full text Add to dashboard Cite

Long non-coding RNAs (lncRNAs) are a class of RNA transcripts that are long (i.e., more than 200 nucleotides) and not translated into proteins. They have recently emerged as potential treatment targets for numerous disorders due to their involvement in multiple cellular functions such as gene regulation, epigenetic modulation, and chromatin organization. This review highlights the current state of lncRNA-based therapeutics, the potential of lncRNAs as drug targets for treating human diseases, the various strategies and types of RNA-based therapeutics, and the complications of developing lncRNA-based drugs. We conclude that lncRNA-based therapeutics represent a promising class of drugs that can potentially treat various human diseases and that further research is needed to fully realize their therapeutic potential.

show abstract

LncRNA SSTR5-AS1 as a Prognostic Marker Promotes Cell Proliferation and Epithelial-to-Mesenchymal Transition in Prostate Cancer

Cited by 4 publications

References 25 publications

A serum LncRNA signature for predicting prognosis of triple-negative breast cancer

A serum LncRNA signature for predicting prognosis of triple-negative breast cancer

A thorough understanding of the role of lncRNA in prostate cancer pathogenesis; Current knowledge and future research directions

Silent players, loud impact: unveiling the therapeutic potentials of LncRNAs

Contact Info

Product

Resources

About